Data from EMC - Curated by EPG Health - Last updated 19 August 2016

Indication(s)

Hydrocortistab Injection is indicated for the local treatment, by intra-articular or periarticular injection, of arthritic conditions such as rheumatoid arthritis and osteoarthritis when few joints are involved. It is also suitable for the symptomatic treatment, by local injection, of certain non-articular inflammatory conditions such as inflamed tendon sheaths and bursae.

Hydrocortistab Injection is not suitable for the production of systemic effects.

 

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Inflammatory bowel disease assessment tools

Inflammatory bowel disease assessment tools

'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Load more

Related Content

Journal articles

Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders.

Anakinra is a biologic response modifier that competitively antagonises the biologic effects of interleukin-1, the ancestor pleiotropic proinflammatory cytokine produced...

Added 3 years ago

Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis.

The aim of this article was to review the available literature data on SC MTX treatment of inflammatory arthritis, with special emphasis on RA and psoriasis, examining differences with oral MTX treatment.

Added 10 months ago

Prediction of response to methotrexate in rheumatoid arthritis.

This narrative review seeks to cover various genotypic and phenotypic characteristics that have been investigated as predictors of treatment response to MTX in RA.

Added 10 months ago

Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis.

Rheumatoid arthritis patients have a high level of pro-inflammatory interleukin-1. Augmenting the blockade of interleukin-1 receptors by external interleukin-1 receptor antagonist modifies the progression of the disease.

Added 11 months ago

Load more

View all 13142 Journal articles items
Guidelines

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis

The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA.

Added 10 months ago

EULAR revised recommendations for the management of fibromyalgia

Fibromyalgia is common with a prevalence of 2% in the general population.1 ,2 However, its diagnosis and management remain a challenge for patients and healthcare professionals.

Added 10 months ago

Spondyloarthritis in over 16s: diagnosis and management

This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice...

Added 10 months ago

BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics

These guidelines provide evidence-based guidance for UK clinicians prescribing biologics for adult patients with axSpA. This includes the criteria for starting treatment, the choice of drug and assessing response to treatment.

Added 1 year ago

BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs

The purpose of this guideline is to provide up-to-date, evidence-based recommendations for the safe use of non-biologic DMARDs in adults (>16 years old).

Added 1 year ago

Load more

View all 1443 Guidelines items

More information

Category Value
Orphan designation No
Type POM
Marketing authorisation holder Amdipharm UK Limited